NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE Stockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) ...

– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC ...

was awarded to the King Faisal Specialist Hospital & Research Centre for revolutionising organ transplantation through ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Gilead Sciences Inc. closed 13.61% below its 52-week high of $119.96, which the company reached on March 10th.

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares ...

Gilead Sciences Inc. closed 15.47% short of its 52-week high of $119.96, which the company reached on March 10th.

In a report released today, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) in Q1 CY2025, with sales flat year on year at $6.67 billion. The ...